U.S., June 3 -- ClinicalTrials.gov registry received information related to the study (NCT07621692) titled 'Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T' on March 02.
Brief Summary: This study is a phase I dose escalation clinical trial aims to evaluate 161Tb-PSMA-I&T, a new generation prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) using Terbium-161 to replace Lutetium-177, its safety, dosimetry, biodistribution, pharmacokinetics, and preliminary efficacy in Taiwanese men with metastatic castration-resistant prostate cancer, and to inform future clinical trials.
Study Start Date: Jan. 01
Study Type: INTERVENTIONAL
Condition:
Metastatic Castr...